Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Editas Medicine (EDIT – Research Report) and Guard...

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)

Barclays analyst Gena Wang maintained a Hold rating on Editas Medicine today and set a price target of $3.00. Wang covers the Healthcare sector, fo...

Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicara Therapeutics Inc. (BCAX – Research Report) an...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EDIT	$2.42	-2.02%	1.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EDIT	$2.42	-2.0%	1.98M
3
4
5
6

EDIT

EDIT

Dividend Overview

Get Editas Medicine Inc. Data in Excel

Get Editas Medicine Inc. Data in Excel